Country-based report: the safety of omalizumab treatment in pregnant patients with asthma

Simple item page
dc.contributor.authorBilun GEMİCİOĞLU
dc.contributor.authorArzu Didem YALÇIN
dc.contributor.authorYavuz HAVLUCU
dc.contributor.authorGül KARAKAYA
dc.contributor.authorLevent ÖZDEMİR
dc.contributor.authorMetin KEREN
dc.contributor.authorSevim BAVBEK
dc.contributor.authorDane EDİGER
dc.contributor.authorİ.Kıvılcım OĞUZÜLGEN
dc.contributor.authorZeynep FERHAN OZSEKER
dc.contributor.authorAyşe Arzu YORGANCIOĞLU
dc.date.accessioned2024-07-24T09:14:35Z
dc.date.available2024-07-24T09:14:35Z
dc.date.issued2021
dc.description.abstractBackground/aim: We aimed to report outcomes of pregnant patients with asthma under omalizumab treatment and their infants in our country. Materials and methods: Patients with asthma who received omalizumab for at least 6 months and at least one dose during their pregnancy were retrospectively evaluated using a questionnaire regarding their disease and therapy and the health of their infants. Results: Twenty pregnant patients and their 23 infant’s data were analyzed. The mean delivery age was 31.8 ± 7.4 years. They received omalizumab for 28.9 ± 21.8 months. Eight (36.4%) patients showed exacerbation of the disease during pregnancy. Forced expiratory volume in 1 s (FEV1) and asthma control test (ACT) scores at the starting time of omalizumab administration, first month of the pregnancy, and after delivery were 71 ± 18%, 83.4 ± 10.5%, and 80.5 ± 13% (FEV1), and 11.9 ± 4.9, 20.2 ± 2.6, and 20.4 ± 2.2 (ACT), respectively. One patient gave birth to twin infants, two patients to two infants each in different years, and 17 to one infant each. Three (13%) infants had low birth weight and five (21.7%) were born prematurely. No congenital anomalies were detected. Seven (30.4%) infants presented atopic diseases during their life. Conclusion: Omalizumab treatment during pregnancy seems to be safe for both patients and their infants.Key words: Exacerbation, gestation, infant, omalizumab, pregnancy, prematurity
dc.identifier.DOI-ID10.3906/sag-2101-341
dc.identifier.issn1300-0144
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/26201
dc.language.isoeng
dc.titleCountry-based report: the safety of omalizumab treatment in pregnant patients with asthma
dc.typeAraştırma Makalesi

Files

Collections

TR-Dizin Koleksiyonu